Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ivacaftor in children aged 6 to 11 years with cystic fibrosis and a G551D CFTR mutation
2008-007479-26Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Ivacaftor with Placebo (2 arms). Primary endpoint: Absolute change from baseline in percent predicted forced expiratory volume in 1 second. Started May 2009; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2008-007479-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007479-26.